Venus receives becomes marketing approval for meropenem in Gulf
The company aims to capture a 25% share of the meropenem market in Saudi Arabia
BS B2B Bureau B2B Connect | Mumbai
Pawan Chaudhary, Chairman and Managing Director, Venus Remedies, said, “Venus has become the first generic drug manufacturer in the world to get marketing approval for this product from the Gulf Cooperation Council (GCC). The $35-million market for meropenem in Saudi Arabia offers a huge opportunity to us, and we are aiming at capturing a 25% share in this market within the first year of the launch itself.”
ALSO READ: GSK to set up Rs 864-crore pharma facility in India
More From This Section
Since Saudi Arabia relies substantially on imports for pharmaceutical products due to insufficient domestic production and lack of indigenous research capabilities to meet the local demands, this marketing authorisation offers a great opportunity to Venus to capture a fair share in the meropenem market in all the GCC markets, including Saudi Arabia. With the SFDA being a major reference authority for regulatory standards and compliance and Venus Remedies emerging as the first and only generics manufacturer for meropenem in Saudi Arabia, apart from AstraZeneca, an innovator pharmaceutical company, Venus enjoys a competitive edge in getting marketing approval for meropenem from all GCC member nations and Middle East countries.
With growing population, pharmaceutical sales in Saudi Arabia, which stood at $4 billion in 2012, are expected to surpass $7 billion by 2018. As evident from this, Saudi Arabia is set to emerge as one of the world’s fastest growing markets in years to come.
Also Read
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Nov 21 2013 | 10:23 AM IST